<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31768050</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein.</ArticleTitle><Pagination><StartPage>1966</StartPage><EndPage>1974</EndPage><MedlinePgn>1966-1974</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0530-0</ELocationID><Abstract><AbstractText>To discover novel genes underlying amyotrophic lateral sclerosis (ALS), we aggregated exomes from 3,864 cases and 7,839 ancestry-matched controls. We observed a significant excess of rare protein-truncating variants among ALS cases, and these variants were concentrated in constrained genes. Through gene level analyses, we replicated known ALS genes including SOD1, NEK1 and FUS. We also observed multiple distinct protein-truncating variants in a highly constrained gene, DNAJC7. The signal in DNAJC7 exceeded genome-wide significance, and immunoblotting assays showed depletion of DNAJC7 protein in fibroblasts in a patient with ALS carrying the p.Arg156Ter variant. DNAJC7 encodes a member of the heat-shock protein family, HSP40, which, along with HSP70 proteins, facilitates protein homeostasis, including folding of newly synthesized polypeptides and clearance of degraded proteins. When these processes are not regulated, misfolding and accumulation of aberrant proteins can occur and lead to protein aggregation, which is a pathological hallmark of neurodegeneration. Our results highlight DNAJC7 as a novel gene for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Sali M K</ForeName><Initials>SMK</Initials><Identifier Source="ORCID">0000-0001-5936-0957</Identifier><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. sfarhan@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. sfarhan@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA. sfarhan@broadinstitute.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howrigan</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0002-7721-4838</Identifier><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbott</LastName><ForeName>Liam E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klim</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0001-8119-2144</Identifier><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topp</LastName><ForeName>Simon D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-5200-3284</Identifier><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrnes</LastName><ForeName>Andrea E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Churchhouse</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phatnani</LastName><ForeName>Hemali</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Bradley N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rampersaud</LastName><ForeName>Evadnie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Gang</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1678-5864</Identifier><AffiliationInfo><Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shatunov</LastName><ForeName>Aleksey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Khleifat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mordes</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Sulagna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ALSGENS Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>FALS Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Project MinE Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>CReATe Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4436-8467</Identifier><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCauley</LastName><ForeName>Jacob L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-1805-1733</Identifier><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;le</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Neurology and Hertie Institute f&#xfc;r Clinical Brain Research, University of T&#xfc;bingen, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;chner</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Chevy Chase, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Tecnica International, Glen Echo, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Southampton and Department of Neurology, University Hospital Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0002-1111-2820</Identifier><AffiliationInfo><Affiliation>Institute for Genomic Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0949-8752</Identifier><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neale</LastName><ForeName>Benjamin M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0003-1513-6077</Identifier><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. bneale@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. bneale@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA. bneale@broadinstitute.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U2C TR002818</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MRF_MRF-060-0003-RG-SMITH</GrantID><Acronym>MRF</Acronym><Agency>MRF</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100695</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SHAW/NOV14/985-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L021803/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900635</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SMITH/APR16/847-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17115</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 MH115727</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485782">DNAJC7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2019 Dec 19;:</RefSource><PMID Version="1">31857710</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING INTERESTS. MN participation is supported by a consulting contract between Data Tecnica International and the National Institute on Aging, NIH, Bethesda, MD, USA, as a possible conflict of interest. MN also consults for Lysosomal Therapeutics Inc, the Michael J. Fox Foundation and Vivid Genomics among others. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31768050</ArticleId><ArticleId IdType="mid">NIHMS1061640</ArticleId><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0530-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0530-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strong MJ et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18, 153&#x2013;174 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH &amp; Veldink J Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol 13, 96&#x2013;104 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A Perspective: Don&#x2019;t keep it in the family. Nature 550, S112 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29045374</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh T et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 19, 571&#x2013;7 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689268</ArticleId><ArticleId IdType="pubmed">26974950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanan V et al. C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. Science 359, 1161&#x2013;1166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008784</ArticleId><ArticleId IdType="pubmed">29420262</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning A et al. A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes 66, 2019&#x2013;2032 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482074</ArticleId><ArticleId IdType="pubmed">28341696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamburg MA &amp; Collins FS The path to personalized medicine. N Engl J Med 363, 301&#x2013;4 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20551152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR et al. The support of human genetic evidence for approved drug indications. Nat Genet 47, 856&#x2013;60 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26121088</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436&#x2013;41 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 84, 324&#x2013;31 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med 9(2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 48, 1037&#x2013;42 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97, 1268&#x2013;1283 e6 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 48, 1043&#x2013;8 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackie RE et al. The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Front Neurosci 11, 254 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433227</ArticleId><ArticleId IdType="pubmed">28559789</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B &amp; Robberecht W The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 10, 661&#x2013;70 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SM et al. The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Can J Neurol Sci 44, 196&#x2013;202 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28003035</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, Gendron TF, Petrucelli L, Hegele RA &amp; Strong MJ OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. Am J Med Genet B Neuropsychiatr Genet 177, 75&#x2013;85 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29080331</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Zaccai J &amp; Brayne C A systematic review of prevalence studies of dementia in Parkinson&#x2019;s disease. Mov Disord 20, 1255&#x2013;63 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16041803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM &amp; Morris JG The Sydney multicenter study of Parkinson&#x2019;s disease: the inevitability of dementia at 20 years. Mov Disord 23, 837&#x2013;44 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerberg L et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 13, 397&#x2013;406 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916642</ArticleId><ArticleId IdType="pubmed">24309898</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium GT The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580&#x2013;5 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010069</ArticleId><ArticleId IdType="pubmed">23715323</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J et al. Structural basis of J cochaperone binding and regulation of Hsp70. Mol Cell 28, 422&#x2013;33 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2096417</ArticleId><ArticleId IdType="pubmed">17996706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampinga HH &amp; Craig EA The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 11, 579&#x2013;92 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003299</ArticleId><ArticleId IdType="pubmed">20651708</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer MP &amp; Bukau B Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 62, 670&#x2013;84 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773841</ArticleId><ArticleId IdType="pubmed">15770419</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerico EM, Tilitsky JM, Meng W &amp; Gierasch LM How hsp70 molecular machines interact with their substrates to mediate diverse physiological functions. J Mol Biol 427, 1575&#x2013;88 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440321</ArticleId><ArticleId IdType="pubmed">25683596</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin MS et al. Autophagy and Alzheimer&#x2019;s Disease: From Molecular Mechanisms to Therapeutic Implications. Front Aging Neurosci 10, 04 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797541</ArticleId><ArticleId IdType="pubmed">29441009</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Lee VM &amp; Trojanowski JQ Parkinson&#x2019;s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 14, 626&#x2013;36 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017235</ArticleId><ArticleId IdType="pubmed">23900411</ArticleId></ArticleIdList></Reference><Reference><Citation>Imarisio S et al. Huntington&#x2019;s disease: from pathology and genetics to potential therapies. Biochem J 412, 191&#x2013;209 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18466116</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Melki R &amp; Kopito R Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11, 301&#x2013;7 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA &amp; Poirier MA Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl, S10&#x2013;7 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer KF, Tatzelt J &amp; Haass C The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27, 336&#x2013;49 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="pubmed">18216876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR &amp; Morimoto RI Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 1471&#x2013;4 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Voisine C, Pedersen JS &amp; Morimoto RI Chaperone networks: tipping the balance in protein folding diseases. Neurobiol Dis 40, 12&#x2013;20 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429345</ArticleId><ArticleId IdType="pubmed">20472062</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehme M et al. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep 9, 1135&#x2013;50 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255334</ArticleId><ArticleId IdType="pubmed">25437566</ArticleId></ArticleIdList></Reference><Reference><Citation>Roodveldt C et al. Chaperone proteostasis in Parkinson&#x2019;s disease: stabilization of the Hsp70/alpha-synuclein complex by Hip. EMBO J 28, 3758&#x2013;70 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790486</ArticleId><ArticleId IdType="pubmed">19875982</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM &amp; Bonini NM Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson&#x2019;s disease. Science 295, 865&#x2013;8 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacker JL et al. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington&#x2019;s disease. J Neurosci 29, 9104&#x2013;14 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739279</ArticleId><ArticleId IdType="pubmed">19605647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG et al. Prominent stress response of Purkinje cells in Creutzfeldt-Jakob disease. Neurobiol Dis 8, 881&#x2013;9 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11592855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones G, Song Y, Chung S &amp; Masison DC Propagation of Saccharomyces cerevisiae [PSI+] prion is impaired by factors that regulate Hsp70 substrate binding. Mol Cell Biol 24, 3928&#x2013;37 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387751</ArticleId><ArticleId IdType="pubmed">15082786</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ et al. The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. Brain 139, 1417&#x2013;32 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845254</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId></ArticleIdList></Reference><Reference><Citation>Udan-Johns M et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genet 23, 157&#x2013;70 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857952</ArticleId><ArticleId IdType="pubmed">23962724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ et al. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener 5, 33 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941488</ArticleId><ArticleId IdType="pubmed">20804554</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology 90, e565&#x2013;e574 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman J et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 37, 355&#x2013;69 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20159555</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 3, e1867 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270899</ArticleId><ArticleId IdType="pubmed">18382657</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum Mol Genet 19, 3440&#x2013;56 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20570967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp PS et al. Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiol Dis 30, 42&#x2013;55 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18255302</ArticleId></ArticleIdList></Reference><Reference><Citation>Novoselov SS et al. Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. PLoS One 8, e73944 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758296</ArticleId><ArticleId IdType="pubmed">24023695</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS-ONLY REFERENCES</Title><Reference><Citation>Ganna A et al. Ultra-rare disruptive and damaging mutations influence educational attainment in the general population. Nat Neurosci 19, 1563&#x2013;1565 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127781</ArticleId><ArticleId IdType="pubmed">27694993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganna A et al. Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. Am J Hum Genet 102, 1204&#x2013;1211 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5992130</ArticleId><ArticleId IdType="pubmed">29861106</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285&#x2013;91 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X Firth logistic regression for rare variant association tests. Front Genet 5, 187 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063169</ArticleId><ArticleId IdType="pubmed">24995013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam HY et al. Performance comparison of whole-genome sequencing platforms. Nat Biotechnol 30, 78&#x2013;82 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076012</ArticleId><ArticleId IdType="pubmed">22178993</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rawe J et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med 5, 28 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706896</ArticleId><ArticleId IdType="pubmed">23537139</ArticleId></ArticleIdList></Reference><Reference><Citation>Samocha KE et al. A framework for the interpretation of de novo mutation in human disease. Nat Genet 46, 944&#x2013;50 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222185</ArticleId><ArticleId IdType="pubmed">25086666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>